Clinical Trials List
2024-08-01 - 2029-12-31
Others
Recruiting9
ICD-10I27.0
Primary pulmonary hypertension
ICD-9416.0
Primary pulmonary hypertension
A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension
-
Trial Applicant
EXCELSIOR BIOPHARMA INCORPORATION
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 吳書豪 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃偉春 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
[Timeline: Week 97]
2. Changes in NT-proBNP concentration from baseline values
[Timeline: Week 97]
Inclution Criteria
Diagnosed with symptomatic idiopathic or heritable PAH classified as WHO functional class III and IV symptoms.
PAH patient, who met NHI criteria, will be scheduled to receive subcutaneous/intravenous treprostinil treatment.
Ability to adhere to the study visit schedule and understand and comply with all protocol requirements.
Will provide completed and signed written informed consents
Exclusion Criteria
Active treatment with injectable prostanoids different from subcutaneous/intravenous treprostinil
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
20 participants
